Revolution Medicines, Inc. announced that it will highlight the groundbreaking results from the Phase 3 Rasolute 302 pivotal clinical trial of Daraxonrasib in previously treated patients with metastatic pancreatic cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.

老虎证券2026/05/31 12:25

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

South32 submits business update presentation to National Storage Mechanism

Reuters•2026/09/15 07:17

Eurozone Bond Yields Rise but Stay Below Monday's Peaks -- Market Talk

Dow Jones•2026/09/15 07:16

Gold: Fed risk keeps bullion vulnerable – ING

FXStreet•2026/09/15 07:15

Carlyle (CG.US) further expands energy business, acquires Parallax for 1 billion Canadian dollars

Carlyle's newly established company plans to acquire Parallax for approximately 1 billion Canadian dollars, continuing its expansion of light crude oil assets in Canada.

智通财经•2026/09/15 07:11